Metastatic Melanoma in a Young Woman Treated with TNF-Alpha Inhibitor for Psoriatic Arthritis: A Case Report

Bianca      Marasini; Luca      Cozzaglio; Laura      Belloli; Marco      Massarotti; Nicola      Ughi; Paolo      Pedrazzoli

doi:10.2174/157488611798280915

Abstract

Introduction: The risk of cancer with the use of biologic agents in rheumatic diseases is still a matter of debate. Published data suggest that the extent of cancer risk might differ according to the type of cancer, and there is recent clinical evidence for a significant increased risk for skin cancer, including melanoma. In contrast with the extensive literature on cancer risk in rheumatoid arthritis, little has been reported on the development of malignancies in spondyloarthroparthies.

Case Presentation: We report the case of an otherwise healthy 31-year-old Italian woman with psoriasic arthritis who developed a melanoma of left third toe with metastatic involvement of regional lymphnodes after a 3-year treatment with the TNF-alpha inhibitor adalimumab.

Conclusion: This case illustrates the possibility of a causal relationship between TNF-alpha inhibitors and melanoma. We believe that vigilance should continue in patients treated with TNF-alpha blocking agents, until the question on the increased incidence of cancers, including skin cancers, associated with these drugs will be defined.

Keywords: Psoriatic arthritis, melanoma, adalimumab, rheumatic disease, spondyloarthroparthies, reginoal lymphnodes, TNF-alpha inhibiotrs, skin cancer